Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447258 | 0.91 | HDAC1 (0.52) | CA12CA1CA7CA14ATM | |
| SCHEMBL4748455 | 0.90 | CA12 (0.57) | CA12CA1CA7CA14ATM | |
| SCHEMBL6243210 | 0.89 | HDAC1 (0.54) | CA12CA1CA7CA14ATM | |
| SCHEMBL29800530 | 0.89 | CA12 (0.48) | CA12CA1CA7CA14ATM | |
| SCHEMBL6445761 | 0.87 | ESRRG (0.55) | CA12CA1CA7CA14ATM | |
| SCHEMBL6236607 | 0.85 | GAA (0.51) | CA12CA1CA7CA14ATM | |
| SCHEMBL9971059 | 0.85 | GAA (0.51) | CA12CA1CA7CA14ATM | |
| SCHEMBL7394476 | 0.84 | CYP1A2 (0.46) | CA12CA1CA7CA14ATM | |
| SCHEMBL1668799 | 0.84 | GAA (0.50) | CA12CA1CA7CA14GAA | |
| SCHEMBL17963188 | 0.84 | CYP17A1 (0.53) | CA12CA1CA7CA14ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-87103808-A | The dopamine-inhibitor | — | 1987-12-09 | — | — | CN | claimed |
| EP-0246888-A2 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1987-11-25 | — | — | EP | claimed |
| EP-4663629-A1 | FLUORINATED PYRAZOLONE COMPOUND AND METHOD FOR PRODUCING SAME | Unimatec Co., Ltd. (JP) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024166973-A1 | FLUORINATED PYRAZOLONE COMPOUND AND METHOD FOR PRODUCING SAME | ユニマテック株式会社 | 2024-08-15 | — | — | WO | disclosed |
| US-20230257908-A1 | MODIFIED DNA-ENCODED CHEMICAL LIBRARY AND METHODS RELATED THERETO | TECHNISCHE UNIVERSITAET DORTMUND (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257908-A1 | MODIFIED DNA-ENCODED CHEMICAL LIBRARY AND METHODS RELATED THERETO | TECHNISCHE UNIVERSITAET DORTMUND (DE) | 2023-08-17 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| EP-4127162-A1 | MODIFIED DNA-ENCODED CHEMICAL LIBRARY AND METHODS RELATED THERETO | Technische Universität Dortmund (DE) | 2023-02-08 | — | — | EP | disclosed |
| US-20220064165-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-03-03 | — | — | US | disclosed |
| WO-2022046989-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021191333-A1 | MODIFIED DNA-ENCODED CHEMICAL LIBRARY AND METHODS RELATED THERETO | TECHNISCHE UNIVERSITÄT DORTMUND (DE) | 2021-09-30 | — | — | WO | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0518955-A4 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | — | 1993-09-22 | — | — | EP | disclosed |
| WO-1993018006-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LIMITED (HK) | 1993-09-16 | — | — | WO | disclosed |
| US-5202312-A | Antiarthritic agents, antiallergens, antidiabetic agents | TANABE SEIYAKU CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0518955-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1992-12-23 | — | — | EP | disclosed |
| WO-1991013904-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1991-09-19 | — | — | WO | disclosed |
| EP-0372818-A2 | Imidazole-containing peptide and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257908-A1 | MODIFIED DNA-ENCODED CHEMICAL LIBRARY AND METHODS RELATED THERETO | DUT, DCTD, DNMT1 | CA12 2245/4885CA1 2446/4885CA7 617/4885 |
| US-20220064165-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | CA12 4229/4885CA1 4587/4885CA7 4338/4885 |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | CA12 4229/4885CA1 4587/4885CA7 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.